Literature DB >> 28609189

A New Kid on the Playground of CRISPR DMD Therapy.

Dongsheng Duan1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28609189      PMCID： PMC5510048          DOI： 10.1089/humc.2017.075

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN： 2324-8637            Impact factor:   5.032


× No keyword cloud information.
  32 in total

1.  AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.

Authors:  Brian Bostick; Jin-Hong Shin; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

2.  Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs.

Authors:  K Yuasa; Y Miyagoe; K Yamamoto; Y Nabeshima; G Dickson; S Takeda
Journal:  FEBS Lett       Date:  1998-03-27       Impact factor: 4.124

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

4.  Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.

Authors:  Sergey Shmakov; Omar O Abudayyeh; Kira S Makarova; Yuri I Wolf; Jonathan S Gootenberg; Ekaterina Semenova; Leonid Minakhin; Julia Joung; Silvana Konermann; Konstantin Severinov; Feng Zhang; Eugene V Koonin
Journal:  Mol Cell       Date:  2015-10-22       Impact factor: 17.970

5.  Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.

Authors:  Yadong Zhang; Yongping Yue; Liang Li; Chady H Hakim; Keqing Zhang; Gail D Thomas; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-05-15       Impact factor: 6.150

Review 6.  An updated evolutionary classification of CRISPR-Cas systems.

Authors:  Kira S Makarova; Yuri I Wolf; Omer S Alkhnbashi; Fabrizio Costa; Shiraz A Shah; Sita J Saunders; Rodolphe Barrangou; Stan J J Brouns; Emmanuelle Charpentier; Daniel H Haft; Philippe Horvath; Sylvain Moineau; Francisco J M Mojica; Rebecca M Terns; Michael P Terns; Malcolm F White; Alexander F Yakunin; Roger A Garrett; John van der Oost; Rolf Backofen; Eugene V Koonin
Journal:  Nat Rev Microbiol       Date:  2015-09-28       Impact factor: 60.633

Review 7.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

Authors:  Niclas E Bengtsson; Jane T Seto; John K Hall; Jeffrey S Chamberlain; Guy L Odom
Journal:  Hum Mol Genet       Date:  2015-10-08       Impact factor: 6.150

8.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

Authors:  Li Xu; Ki Ho Park; Lixia Zhao; Jing Xu; Mona El Refaey; Yandi Gao; Hua Zhu; Jianjie Ma; Renzhi Han
Journal:  Mol Ther       Date:  2015-10-09       Impact factor: 11.454

9.  Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.

Authors:  Ignazio Maggio; Luca Stefanucci; Josephine M Janssen; Jin Liu; Xiaoyu Chen; Vincent Mouly; Manuel A F V Gonçalves
Journal:  Nucleic Acids Res       Date:  2016-01-13       Impact factor: 16.971

10.  CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.

Authors:  Yu Zhang; Chengzu Long; Hui Li; John R McAnally; Kedryn K Baskin; John M Shelton; Rhonda Bassel-Duby; Eric N Olson
Journal:  Sci Adv       Date:  2017-04-12       Impact factor: 14.136
View more
  1 in total

1.  Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy.

Authors:  Zhanguo Gao; Aiping Lu; Alexes C Daquinag; Yongmei Yu; Matthieu Huard; Chieh Tseng; Xueqin Gao; Johnny Huard; Mikhail G Kolonin
Journal:  Biomolecules       Date:  2021-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.